共 48 条
[3]
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
[J].
LANCET INFECTIOUS DISEASES,
2021, 21 (02)
:226-240
[6]
Davies Sally C, 2021, Future Healthc J, V8, pe251, DOI 10.7861/fhj.2021-0087
[7]
De Waele J, 2014, BMC INFECT DIS, V14, DOI [10.1186/1471-2334-14-420, 10.1186/1471-2334-14-193]
[8]
Emeraud C, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00010-19, 10.1128/aac.00010-19]
[10]
Falagas ME, 2011, FUTURE MICROBIOL, V6, P653, DOI [10.2217/FMB.11.49, 10.2217/fmb.11.49]